MoonLake Immunotherapeutics
MLTX · NASDAQ
Bulios Fair Price
$7.28
36.5% downside
Current Price
$11.47
According to Bulios Fair Price, MLTX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
MoonLake Immunotherapeutics is a biotechnology company focused on developing immunotherapies for the treatment of autoimmune diseases and cancer. The company utilizes advanced technology that combines biological molecules and monoclonal antibodies for targeted therapy, focusing on specific immune pathways that are critical for the development of various diseases. MoonLake specializes in developing drugs for conditions such as psoriasis, cancer, and other autoimmune disorders, aiming to provide new and effective therapeutic options for patients with these serious diseases.
Sector
Healthcare
Industry
Biotechnology
CEO
Jorge Santos da Silva
Employees
130
Headquarters
Zug
Upcoming events
Earnings
Upcoming earnings report